Maynard Um
-
-
-
-
-
-
-
Canaccord Genuity Downgrades Akero Therapeutics (AKRO) to Hold
-
-
-
-
-
-
-
TD Cowen Starts Akero Therapeutics (AKRO) at Buy
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) PT Raised to $80 at Citi
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
-
-
-
-
-
-
-
Citi Starts Akero Therapeutics (AKRO) at Buy
-
-
-
-
-
-
419,329 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

